Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	VBI Vaccines	Collegium Pharmaceutical	Odonate Therapeutics	ADVANZ PHARMA	Amphastar Pharmaceuticals
Symbol	NASDAQ:VBIV	NASDAQ:COLL	NASDAQ:ODT	OTCMKTS:CXRXF	NASDAQ:AMPH
Price Information
Current Price	$2.95	$23.60	$3.55	$16.84	$17.62
52 Week Range	Buy	Hold	Hold	N/A	Hold
MarketRank™
Overall Score	1.5	1.4	1.8	0.5	1.5
Analysis Score	3.6	1.1	3.0	0.0	2.1
Community Score	3.2	2.5	2.1	2.3	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	2.5	0.0	0.8
Earnings & Valuation Score	0.0	3.1	1.3	0.0	1.9
Analyst Ratings
Consensus Recommendation	Buy	Hold	Hold	N/A	Hold
Consensus Price Target	$7.00	$25.00	$19.33	N/A	$21.67
% Upside from Price Target	137.29% upside	5.93% upside	444.60% upside	N/A	22.97% upside
Trade Information
Market Cap	$713.75 million	$818.85 million	$128.17 million	$823.92 million	$837.44 million
Beta	2.14	1.27	0.66	N/A	0.87
Average Volume	6,455,847	543,633	3,622,045	14,896	194,287
Sales & Book Value
Annual Revenue	$2.22 million	$296.70 million	N/A	$508.32 million	$322.36 million
Price / Sales	337.53	2.80	N/A	1.62	2.61
Cashflow	N/A	N/A	N/A	N/A	$0.72 per share
Price / Cash	N/A	N/A	N/A	N/A	24.42
Book Value	$0.50 per share	$2.61 per share	$5.06 per share	$0.31 per share	$9.11 per share
Price / Book	5.90	9.04	N/A	54.34	1.93
Profitability
Net Income	$-54,810,000.00	$-22,720,000.00	$-111,820,000.00	$-196,020,000.00	$48.94 million
EPS	($0.46)	($0.68)	($4.05)	N/A	$0.36
Trailing P/E Ratio	N/A	48.16	N/A	N/A	125.86
Forward P/E Ratio	N/A	14.30	N/A	∞	15.87
P/E Growth	N/A	0.73	N/A	N/A	N/A
Net Margins	-2,837.73%	5.71%	N/A	-19.88%	1.97%
Return on Equity (ROE)	-36.69%	12.64%	-85.75%	N/A	5.50%
Return on Assets (ROA)	-28.29%	3.15%	-71.45%	-3.08%	4.04%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.10%	1.27%	N/A	N/A	0.07%
Current Ratio	9.06%	1.08%	6.68%	1.75%	2.86%
Quick Ratio	8.95%	1.01%	6.68%	1.24%	1.73%
Ownership Information
Institutional Ownership Percentage	52.13%	N/A	96.00%	N/A	55.08%
Insider Ownership Percentage	10.50%	8.08%	48.90%	N/A	29.80%
Miscellaneous
Employees	127	234	134	429	1,980
Shares Outstanding	254.01 million	35.20 million	38.60 million	48.91 million	47.69 million
Next Earnings Date	5/5/2021 (Estimated)	5/6/2021 (Confirmed)	4/27/2021 (Estimated)	5/12/2021 (Estimated)	5/6/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $97.12 Million americanbankingnews.com - April 13 at 3:32 AM
	$0.19 EPS Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter americanbankingnews.com - April 11 at 12:08 PM
	Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Brokerages americanbankingnews.com - April 9 at 10:48 AM
	Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt? finance.yahoo.com - April 9 at 9:20 AM
	Have Insiders Been Selling Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares This Year? nasdaq.com - April 7 at 9:20 AM
	Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 6 at 6:32 PM
	Raymond James Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP) smarteranalyst.com - April 5 at 7:07 PM
	Amphastar Pharmaceuticals (AMPH) Receives a Buy from Northland Securities smarteranalyst.com - March 30 at 12:22 PM
	FDA Approves New Drug Application For Amphastar’s Dextrose Injection finance.yahoo.com - March 30 at 12:22 PM
	Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection finance.yahoo.com - March 29 at 6:19 AM
	Raymond James Keeps a Hold Rating on Amphastar Pharmaceuticals (AMPH) smarteranalyst.com - March 16 at 10:05 AM
	Amphastar: Q4 Earnings Snapshot finance.yahoo.com - March 15 at 6:56 PM
	Amphastar: Q4 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - March 15 at 6:56 PM
	Recap: Amphastar Pharmaceuticals Q4 Earnings benzinga.com - March 15 at 6:56 PM
	Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020 finance.yahoo.com - March 15 at 6:56 PM
	Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates finance.yahoo.com - March 15 at 6:56 PM
	Raymond James Sticks to Their Hold Rating for PLx Pharma (PLXP) smarteranalyst.com - March 15 at 1:32 PM
	Here's what Wall Street expects from Amphastar Pharmaceuticals's earnings report markets.businessinsider.com - March 13 at 2:27 PM
	Hyaluronidase Market Revenue Growth Predicted by 2021-2030 \| Amphastar Pharmaceuticals Inc., PrimaPharma Inc. marketwatch.com - March 9 at 9:35 AM
	Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March ... apnews.com - March 8 at 6:28 PM
	Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021 finance.yahoo.com - March 8 at 6:28 PM
	FDA approves 1st generic glucagon injections for severe hypoglycemia ems1.com - February 25 at 8:22 PM
	Teva Pharmaceutical (TEVA) Gets a Buy Rating from Raymond James smarteranalyst.com - February 16 at 2:33 PM
	What Percentage Of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Do Insiders Own? finance.yahoo.com - February 8 at 7:26 AM
	Raymond James Believes Teva Pharmaceutical (TEVA) Still Has Room to Grow smarteranalyst.com - January 19 at 10:04 PM

Date	Company	Brokerage	Action
2/25/2021	VBI Vaccines	Jefferies Financial Group	Initiated Coverage
8/27/2020	VBI Vaccines	Oppenheimer	Reiterated Rating
8/26/2020	VBI Vaccines	Raymond James	Upgrade
6/29/2020	VBI Vaccines	BMO Capital Markets	Reiterated Rating
3/6/2020	VBI Vaccines	Canaccord Genuity	Reiterated Rating
1/11/2021	Collegium Pharmaceutical	HC Wainwright	Boost Price Target
12/29/2020	Collegium Pharmaceutical	Needham & Company LLC	Reiterated Rating
7/14/2020	Collegium Pharmaceutical	BWS Financial	Initiated Coverage
5/26/2020	Collegium Pharmaceutical	Guggenheim	Initiated Coverage
2/28/2020	Collegium Pharmaceutical	William Blair	Reiterated Rating
2/12/2020	Collegium Pharmaceutical	Piper Sandler	Boost Price Target
2/7/2020	Collegium Pharmaceutical	Cantor Fitzgerald	Boost Price Target
3/22/2021	Odonate Therapeutics	Lifesci Capital	Downgrade
3/22/2021	Odonate Therapeutics	The Goldman Sachs Group	Lower Price Target
3/22/2021	Odonate Therapeutics	Cowen	Downgrade
9/9/2020	Odonate Therapeutics	Ci Capital	Reiterated Rating
3/15/2019	ADVANZ PHARMA	Bloom Burton	Reiterated Rating
3/23/2021	Amphastar Pharmaceuticals	Wells Fargo & Company	Lower Price Target
10/5/2020	Amphastar Pharmaceuticals	Northland Securities	Upgrade
3/13/2019	Amphastar Pharmaceuticals	Piper Jaffray Companies	Downgrade

(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources